DUSP4 and breast carcinoma: These results together demonstrate that these enhancers activate CCND1, in a combinatorial manner, due to enhancer hijacking while also acting in their canonical role of activating DUSP4. CCND1 is overexpressed in 50% of breast cancers, which has been partially attributed to gene amplification46.